The field of AMR is dynamic and rapidly evolving, and the treatment of antimicrobial-resistant infections will continue to challenge clinicians. As newer antibiotics against resistant pathogens are incorporated into clinical practice, we are learning more about their effectiveness and propensity to resistance. This treatment guidance focusing on ESBL-E, CRE, and DTR-P. aeruginosa will be updated annually and is available at: -guideline/amr-guidance/. A second AMR treatment guidance focusing on the treatment of infections caused by AmpC-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections is available at: -guideline/amr-guidance-2.0/.
antibiotic smart use guideline pdf download
2ff7e9595c
Comments